Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci

Intensive Care Medicine

Volumn 28, Issue 8, 2002, Pages 1157-1160

  Sander, A ^a   Beiderlinden, M ^b   Schmid, E ^b   Peters, J ^b  

^a Klinikum Niederrhein gGmbH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antibiotics; Infectious disease; Multiple organ dysfunction; Staphylococcus aureus; Staphylococcus epidermidis

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; METICILLIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATION; CAUSE OF DEATH; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RESPIRATORY FAILURE; SIDE EFFECT; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CRITICAL CARE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VIRGINIAMYCIN;

EID: 0036366887     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1358-7     Document Type: Article

References (20)

1. Dissemination in Japanese hospitals of strains of staphylococcus aureus heterogeneously resistant to vancomycin
2. Emergence of vancomycin resistance in staphylococcus aureus
3. First critical isolate of vancomycin-intermediate staphylococcus aureus in a French hospital
4. Penetration of vancomycin into human lung tissue
5. Penetration of vancomycin into mediastinal and cardiac tissues in humans
6. Glycopeptide tolerance in bacteria causing endocarditis
7. Infectious complications of indwelling vascular catheters
8. Quinupristin/dalfopristin: A review of its use in the management of serious gram-positive infections
9. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin
10. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin
11. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant or failing prior therapy
12. The Vitek analyser for routine bacterial identification and susceptibility testing: Protocols, problems and pitfalls
13. Quinupristin-dalfopristin: Spectrum of activity, pharmacokinetics and initial clinical experience
14. Antibacterial activity of quinupristin-dalfopristin. Rationale for clinical use
15. European glycopeptide susceptibility survey of gram-positive bacteria for 1995
16. Sepsis: A new hypothesis for pathogenesis of the disease process
17. The continuing importance of staphylococci as major hospital pathogens
18. Coagulase-negative staphylococcal bacteraemia with special reference to septic shock: Experience in an intensive care unit
19. Increasing bacteremia due to coagulase-negative staphylococci: Fiction or reality?
20. The pathogenesis of sepsis